34.38
+5.72%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Castle Biosciences
From its filings with the US Securities and Exchange Commission
Castle Biosciences is based in Friendswood, Texas and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CSTL. The SEC classifies its business as medical laboratories. In the fiscal year to 31 December 2025, it reported revenue of $344.2m and a net loss of $24.2m. At that date it held total assets of $578.6m and shareholders' equity of $470.9m. By business, Dermatologic brought in 62.9% of revenue, followed by Non Dermatologic at 37.1%.
Castle Biosciences is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (“BE”), atopic dermatitis (“AD”), uveal melanoma (“UM”).
Since our inception in 2008, it has been our vision to transform disease management by keeping people first: patients, clinicians, employees and investors. This foundational strategy remains the guidepost for the direction of our company and the basis of long-term value creation.
Our tests are designed to deliver personalized information to help better inform clinical care decisions. For our core tissue-based tests, we use multi-analyte assays with algorithmic analysis (“MAAA”) to characterize an individual patient’s biology and generate clinically actionable information. Depending on the specific test, this information may be used to provide information to help guide treatment and patient management decisions including potential responsiveness to therapy and to assist in the diagnosis of a disease.
Our portfolio consists of test offerings to aid clinicians in the diagnosis and treatment of cancers or precancerous diagnoses in the fields of dermatology, gastroenterology and ophthalmology, and most recently includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 25 Jul 2019
- Employees
- 883
- Website
- castlebiosciences.com ↗
- Head office
- 1500 W. PARKWOOD AVE., FRIENDSWOOD, TX, 77546
- Incorporated in
- DE
- Classification
- Services-Medical Laboratories
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Mr. Daniel BradburyIndependent Chairman of the Board$297,147
- Mr. Derek MaetzoldPresident, Chief Executive Officer, Founder, Director, since 2007$6.9m
- Mr. Frank StokesChief Financial Officer$2.3m
- Ms. Kristen OelschlagerChief Operating Officer$2.4m
- Mr. Tobin JuvenalChief Commercial Officer$2.4m
- Ms. Kimberlee CapleIndependent Director$267,147
- Mr. G. Bradley ColeIndependent Director$279,647
- Mr. Rodney CottonIndependent Director$549,999
- Ms. Ellen GoldbergIndependent Director$264,647
- Mr. Miles HarrisonIndependent Director$277,147
- Ms. Tiffany OlsonIndependent Director$319,683
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 38
- Environment
- 2
- Social
- 41
- Governance
- 72
- Women in the workforce
- 64%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Castle Biosciences Inc is a prominent player in the biotechnology industry, known for their innovative products and services.
- The company has a strong portfolio of advanced diagnostic tests for skin cancer and other dermatologic conditions, offering reliable and accurate results.
- Castle Biosciences Inc has established a solid reputation for their expertise and comprehensive understanding of personalized medicine, which further enhances their market position.
- The company's dedicated and skilled team of professionals is a key strength, ensuring high-quality research, development, and customer support.
Weaknesses
- One potential weakness for Castle Biosciences Inc is their reliance on a limited range of diagnostic tests. Diversifying their product offerings could help mitigate this risk.
- The company may face challenges in terms of regulatory compliance and obtaining necessary approvals for their diagnostic tests, which could result in delays or limitations on market entry.
- Castle Biosciences Inc may also be more vulnerable to competition from larger, established biotechnology companies that have greater resources and market presence.
Opportunities
- There is a growing demand for personalized medicine and advanced diagnostics, presenting significant opportunities for Castle Biosciences Inc to expand their market share.
- The company can explore collaborations and partnerships with healthcare providers and pharmaceutical companies to leverage their expertise and reach a wider customer base.
- Expanding into international markets could also be a viable opportunity for Castle Biosciences Inc to broaden their customer reach and increase revenue.
Threats
- Competition in the biotechnology industry is intense, with new entrants and established players constantly emerging. Castle Biosciences Inc must stay vigilant and continuously innovate to stay ahead.
- Evolving healthcare regulations and policies can pose challenges for Castle Biosciences Inc, as compliance and adherence to these regulations may require significant resources and adaptations.
- Market uncertainties and economic fluctuations can also impact the demand for diagnostic tests, making it essential for Castle Biosciences Inc to maintain financial stability and diversify revenue streams.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.